RATIONALE: Emerging evidence from agonist-antagonist studies suggests a role for the dopamine D(3) receptor subtype in the regulation of PPI in animals, but such evidence is lacking for human subjects. OBJECTIVES: This study examines the effect of the preferential D(3) agonist ropinirole on PPI in humans. METHODS: PPI was tested in 12 healthy men in three sessions associated with ropinirole 0.25 mg, ropinirole 0.5 mg, or placebo according to a balanced, crossover, double-blind design. Two prepulses (75- and 85-dB white noise bursts) and two lead intervals (50 and 80 ms) were employed. RESULTS:Ropinirole 0.5 mg significantly reduced prepulse inhibition (PPI) with both prepulses at the 80-ms lead intervals. There was no effect of treatment on startle amplitude and habituation. CONCLUSIONS: These results suggest a role for the dopamine D(3) receptor in the mediation of human PPI, although a contribution from ropinirole's agonistic activity at the D(2) receptor cannot be entirely excluded. Firm conclusions on the role of the D(3) receptor in the modulation of human PPI can only be drawn with the use of genetic approaches or more selective ligands for this receptor.
RCT Entities:
RATIONALE: Emerging evidence from agonist-antagonist studies suggests a role for the dopamine D(3) receptor subtype in the regulation of PPI in animals, but such evidence is lacking for human subjects. OBJECTIVES: This study examines the effect of the preferential D(3) agonist ropinirole on PPI in humans. METHODS: PPI was tested in 12 healthy men in three sessions associated with ropinirole 0.25 mg, ropinirole 0.5 mg, or placebo according to a balanced, crossover, double-blind design. Two prepulses (75- and 85-dB white noise bursts) and two lead intervals (50 and 80 ms) were employed. RESULTS:Ropinirole 0.5 mg significantly reduced prepulse inhibition (PPI) with both prepulses at the 80-ms lead intervals. There was no effect of treatment on startle amplitude and habituation. CONCLUSIONS: These results suggest a role for the dopamine D(3) receptor in the mediation of human PPI, although a contribution from ropinirole's agonistic activity at the D(2) receptor cannot be entirely excluded. Firm conclusions on the role of the D(3) receptor in the modulation of human PPI can only be drawn with the use of genetic approaches or more selective ligands for this receptor.
Authors: Neal R Swerdlow; Jody M Shoemaker; Ronald Kuczenski; Michele J Bongiovanni; Alaina C Neary; Laura S Tochen; Richard L Saint Marie Journal: Neurosci Lett Date: 2006-04-27 Impact factor: 3.046
Authors: C Reavill; S G Taylor; M D Wood; T Ashmeade; N E Austin; K Y Avenell; I Boyfield; C L Branch; J Cilia; M C Coldwell; M S Hadley; A J Hunter; P Jeffrey; F Jewitt; C N Johnson; D N Jones; A D Medhurst; D N Middlemiss; D J Nash; G J Riley; C Routledge; G Stemp; K M Thewlis; B Trail; A K Vong; J J Hagan Journal: J Pharmacol Exp Ther Date: 2000-09 Impact factor: 4.030
Authors: P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross Journal: CNS Neurol Disord Drug Targets Date: 2006-02 Impact factor: 4.388
Authors: Tanja Jovanovic; Sandor Szilagyi; Subhajit Chakravorty; Ana M Fiallos; Barbara J Lewison; Arti Parwani; Marion P Schwartz; Stephen Gonzenbach; John P Rotrosen; Erica J Duncan Journal: Psychophysiology Date: 2004-05 Impact factor: 4.016
Authors: Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu Journal: Ageing Res Rev Date: 2019-11-22 Impact factor: 10.895
Authors: Erika J Wolf; Karen S Mitchell; Mark W Logue; Clinton T Baldwin; Annemarie F Reardon; Alison Aiello; Sandro Galea; Karestan C Koenen; Monica Uddin; Derek Wildman; Mark W Miller Journal: J Trauma Stress Date: 2014-08
Authors: Alison K Berger; Thomas Green; Steven J Siegel; Eric J Nestler; Ronald P Hammer Journal: Biol Psychiatry Date: 2010-10-30 Impact factor: 13.382
Authors: Martin Weber; Wei-Li Chang; John P Durbin; Paula E Park; Robert R Luedtke; Robert H Mach; Neal R Swerdlow Journal: Pharmacol Biochem Behav Date: 2009-05-06 Impact factor: 3.533
Authors: Neal R Swerdlow; Sophia A Lelham; Ashley N Sutherland Owens; Wei-Li Chang; Sebastiaan D T Sassen; Jo A Talledo Journal: Psychopharmacology (Berl) Date: 2009-06-09 Impact factor: 4.530